| Literature DB >> 35885445 |
Abstract
Screening for genomic sequence variants in genes of predictive and prognostic significance is an integral part of precision medicine. Next-generation sequencing (NGS) technologies are progressively becoming platforms of choice to facilitate this, owing to their massively parallel sequencing capability, which can be used to simultaneously screen multiple markers in multiple samples for a variety of variants (single nucleotide and multi nucleotide variants, insertions and deletions, gene copy number variations, and fusions). A crucial step in the workflow of targeted NGS is the enrichment of the genomic regions of interest to be sequenced, against the whole genomic background. This ensures that the NGS effort is focused to predominantly screen target regions of interest with minimal off-target sequencing, making it more accurate and economical. Polymerase chain reaction-based (PCR, or amplicon-based) and hybridization capture-based methodologies are the two prominent approaches employed for target enrichment. This review summarizes the basic principles of target enrichment utilized by these methods, their multiple variations that have evolved over time, automation approaches, overall comparison of their advantages and drawbacks, and commercially available choices for these methodologies.Entities:
Keywords: NGS; amplicon; hybridization capture; next-generation sequencing; polymerase chain reaction; target enrichment
Year: 2022 PMID: 35885445 PMCID: PMC9318977 DOI: 10.3390/diagnostics12071539
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Target Enrichment Approaches for NGS. The underlying principles of the two prominent target enrichment technologies are depicted schematically. (A) The PCR amplicon-based method employs PCR amplification using sequence-specific, target-spanning primers to amplify and enrich the genomic regions of interest (targets). Postamplification, in a ligation step, sequencing adapters and barcode indexes are included to generate the genomic library for sequencing. (B) In the hybrid capture method, the input genomic DNA is fragmented using enzymatic or acoustic methods followed by ligation of adapters and barcode indices to generate a genomic library. This is subjected to hybridization using biotin-labeled target sequence-specific probes followed by capture of the hybridized probes using Streptavidin magnetic beads to isolate genomic regions of interest for sequencing.
Figure 2Variations of the Hybrid Capture Target Enrichment Methods. Some examples of variations of the hybrid capture methods are depicted. (A) Molecular inversion probe-based enrichment, where probes with sequences complementary to the target region of interest are used. Binding of the probes, followed by extension ligation results in circularized DNA with the target region included. Using these as templates, subsequently, a universal primer is used to linearize, amplify, and generate the sequencing library. (B) Tagmentation method, where transposomes are used to fragment double-stranded DNA and tag with sequencing adapters in a single step. This tagged genomic library is amplified using adapter-specific primers followed by hybrid capture with target-specific probes to isolate target-enriched library for sequencing. (C) Haloplex method, where biotin-labeled circularization probes are used to bind to endonuclease-digested DNA, followed by extension ligation, which results in circularized DNA with targeted region of interest, which is amplified using a universal primer to generate enriched library for sequencing.
Comparison of Amplicon-Based and Hybrid Capture-Based Target Enrichment. A comparison of the principles, workflow, overall performance, and commercially available options is provided.
| Hybrid Capture-Based Enrichment | PCR Amplicon-Based Enrichment | |
|---|---|---|
|
| Hybridization capture-based enrichment using single-stranded DNA or RNA probes complementary to the genomic regions of interest | PCR-based amplification using sequence-specific primers flanking genomic regions of interest |
|
| Requires relatively high quantity of nucleic acid input | Compatible with low quantity of nucleic acid input |
|
| Compatible with challenging sample types; however, success depends on obtaining sufficient yield | Compatible with challenging sample types (e.g., FFPE and decalcified samples) |
|
| Required. | Not required |
|
| Relatively long due to the hybrid capture step | Significantly shorter workflow |
|
| High complexity workflow with multiple steps | Relatively simple workflow |
|
| No limitations and can include any number of gene targets. Preferred methodology for large panels and | Generally suited for smaller number of gene targets. Limited by the multiplexing capability of the primers |
|
| Higher uniformity of target enrichment and | Relatively low target enrichment uniformity and higher sequencing failures |
|
| Relatively high. | Lower off-target sequencing rate |
|
| SureSelect (Agilent Technologies) | AmpliSeq (ThermoFisher Scientific) |
Comparison of Commercial Amplicon-Based and Hybrid Capture-Based Target Enrichment Methods. A snapshot summary of some published studies comparing commercial target enrichment products, their vendors, enrichment approaches, workflow, samples tested, and their overall performance is provided.
| Commercial Enrichment | Enrichment | Genome Targets and Sample Types | Findings | Reference |
|---|---|---|---|---|
| Fluidigm Access array (Fluidigm) | Microfluidic PCR | DNA from 8 human bladder cancer cell lines (both fresh and formalin-fixed samples). 24 mutations in 6 genes ( | Complete concordance of results for fresh DNA | [ |
| SureSeq panel | ||||
| (Oxfore Gene Technology) | Hybrid-capture | |||
| Ion AmpliSeq | ||||
| (ThermoFisher Scientific) | PCR amplicon-based | |||
| SureSelect (Agilent Technologies) | Hybrid capture | Single nucleotide variants (SNVs) and copy number variations (CNVs) in a panel of 257 cancer-related genes. | Comparable cost of workflow across the methods | [ |
| Haloplex (Agilent Technologies) | Hybrid capture | |||
| Nextera (Illumina Inc) | Hybrid capture | |||
| SeqCap EZ (Roche Nimblegen) | Hybrid capture | |||
| SureSelect (Agilent Technologies) | Hybrid capture | Whole-Exome Sequencing | Hybrid capture methods provided better library complexity, uniformity of coverage, analytical sensitivity, and specificity | [ |
| Haloplex (Agilent Technologies) | Hybrid capture | |||
| SeqCap EZ (Roche Nimblegen) | Hybrid capture | |||
| Ion AmpliSeq | ||||
| (ThermoFisher Scientific) | PCR amplicon-based | |||
| TruSight (Illumina Inc) | Hybrid capture | TruSight performed better with regards to uniformity of sequencing, analytical specificity, and detection of mutations and CNVs | [ | |
| TruSeq custom amplicon | ||||
| (Illumina Inc) | PCR amplicon-based | |||
| Avenio CtDNA panel (Roche) | Hybrid capture | Screening circulating cell-free tumor DNA (ctDNA) for cancer-related markers | QiaSeq had shorter workflow | [ |
| QIAseq Human Comprehensive Cancer | ||||
| panel (Qiagen) | PCR amplicon-based |